H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $100.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).

The analyst commented: "In a press release earlier this month, MoonLake reported its 1Q25 financial results. The company remains slated to have a crucial year, with the most impactful potential catalyst being the release of top-line data from the Phase 3 VELA program with lead candidate sonelokimab (SLK) in hidradenitis suppurativa (HS) in September. Investors should be aware that MoonLake has completed VELA enrollment—at a pace ~40% faster than previous industry benchmarks—and disclosed baseline characteristics of the patient population in these studies, which replicates the properties of the population enrolled in the earlier proof-of-concept MIRA Phase 2 study. From our vantage point, replication of the patient baseline characteristics in MIRA constitutes a crucial risk-mitigating factor for the VELA studies. We reiterate our Buy rating and 12-month price target of $100 per share."

For an analyst ratings summary and ratings history on Moonlake Immunotherapeutics click here. For more ratings news on Moonlake Immunotherapeutics click here.

Shares of Moonlake Immunotherapeutics closed at $38.93 yesterday.

You May Also Be Interested In

• Nebius Group (NBIS) PT Raised to $300 at Compass Point
• Pyxis Oncology, Inc. (PYXS) Misses Q2 EPS by 4c
• STAAR Surgical (STAA) Tops Q2 EPS by 2c, Beats on Revenue